The FDA has granted breakthrough therapy designation to privosegtor for optic neuritis, a common symptom of multiple ...
Privosegtor is advancing in the registrational PIONEER program across 2 key optic neuropathies, representing an unaddressed potential market of $7 billion in the U.S. Privosegtor achieved an average ...
Optic Neuritis: Clinical Features Optic neuritis refers to inflammation of the optic nerve. The term may be used broadly in reference to many causes of optic nerve inflammation including systemic ...
ZUG, Switzerland, Oct. 06, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (OCS) (“Oculis”), a global biopharmaceutical company focused on innovations addressing neuro-ophthalmic diseases with significant ...
Vision – To be the world's leading and most trusted provider of information and services that will make a real difference in clinical practice and improve outcomes for patients. Mission – To lead the ...
The US Food and Drug Administration has granted breakthrough therapy designation to Oculis’ neuroprotective candidate ...
Your ability to see the world around you hinges on how well different structures in your eye perform their designated jobs. The optic nerve — actually a bundle of more than one million nerve fibers — ...
Phase 2 ACUITY trial results for Privosegtor (OCS-05) in acute optic neuritis to be presented in EURETINA late-breaking session Expanded data analysis from Phase 3 Stage 1 DIAMOND program for OCS-01 ...
"Patients with anti-AQP4-Ab may basically need long-term relapse prevention, because they surely experience much higher relapse activity, with much worse neurological disturbance…In MOGAD patients, ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback